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AbstrACt
Introduction Few treatment options exist for patients with 
systemic lupus erythematosus (SLE) who fail conventional 
therapy. Although widely used to treat lupus, the efficacy 
of B cell depletion therapy using rituximab has not been 
demonstrated in randomised clinical trials. Following 
rituximab, elevated levels of serum B cell activating 
factor (BAFF) have been associated with failure to remit 
or subsequent lupus relapse. The administration of 
belimumab, a monoclonal antibody specific for BAFF and 
approved for lupus therapy, could potentiate the efficacy of 
rituximab and enable longer periods of disease remission. 
The aim of this trial is to assess the safety and efficacy of 
belimumab following rituximab in patients with SLE.
Methods and analysis BEAT Lupus is a double- blind, 
randomised, placebo controlled, phase II clinical trial. 
Patients with SLE commencing a treatment cycle of 
rituximab (two 1g infusions, 2 weeks apart) as standard 
of care will be randomised to receive belimumab or 
placebo, 4 to 8 weeks following the first rituximab infusion. 
Belimumab or placebo infusions are administered for 
52 weeks. The primary outcome measure is anti- double 
stranded DNA (anti- dsDNA) antibody levels at 52 weeks. 
Secondary outcomes include measures of adverse events, 
lupus disease activity and cumulative steroid dose. The 
kinetics of B cell repopulation will be assessed in a 
subgroup of participants. Belimumab administration after 
rituximab may provide a novel therapeutic pathway for 
patients with active lupus if safety is demonstrated in this 
proof of concept study, and lower anti- dsDNA antibodies 
levels are achieved in those patients treated with 
belimumab compared with placebo.
Ethics and dissemination The protocol has been 
reviewed and approved by the Hampstead Research 
Ethics Committee - London (reference 16/LO/1024). 
Trial information is available at https://www. isrctn. 
com/ ISRCTN47873003, and the results of this trial will 
be submitted for publication in relevant peer- reviewed 
journals. Key findings will also be presented at national 
and international conferences.
trial registration number ISRCTN47873; date assigned 
to the registry: 28 November 2016. The stage is pre- 
results.
IntroduCtIon
Despite burgeoning research into the 
pathogenesis of systemic lupus erythema-
tosus (SLE), the introduction of novel treat-
ments into the clinic has been slow. This is 
in contrast to some other immune mediated 
rheumatic diseases, in particular rheumatoid 
arthritis (RA), for which several novel ther-
apies developed through increased under-
standing of disease pathogenesis have made a 
substantial impact on patient care. A number 
strengths and limitations of this study
 ► Double- blind, randomised, placebo controlled trial 
in lupus patients refractory to conventional therapy 
thereby reflecting real world practise while eliminat-
ing expectation of treatment benefit.
 ► Trial recruitment at point of randomisation to beli-
mumab or placebo, rather than before rituximab, to 
improve safety and mitigate loss of patients due to 
adverse events following rituximab.
 ► Small sample size because of safety considerations 
prevailing at the conception of the trial may limit 
analyses.
 ► Trial design stipulates reduction in concomitant ste-
roid and immunosuppressant dosage to maximise 
any potential difference between belimumab and 
placebo.
 ► The experimental medicine component of this tri-
al will enable a greater understanding of response 
to combination B cell depletion and belimumab 
therapy.
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of reasons may account for the disparity between SLE and 
RA including the greater use of corticosteroids which 
limits the potential for novel treatments to show superi-
ority in clinical trials; the multisystem nature of lupus and 
insufficient understanding of the key factors that drive 
disease.1
Rituximab, a chimeric anti- CD20 monoclonal antibody, 
has shown significant, though variable, efficacy in open- 
label studies, including both single- centre2–5 and multi-
centre studies6–9; as well as a systematic review of off- label 
use.6 However, two large, phase III, randomised placebo- 
controlled trials in non- renal lupus (EXPLORER)10 11 and 
renal lupus (LUNAR),12 failed to meet their primary end- 
points. Nevertheless, the European League Against Rheu-
matism have accepted that therapy with rituximab should 
be considered in organ- threatening, refractory lupus.13 
In addition, National Health Service (NHS) England 
have approved rituximab as part of standard of care in 
patients with moderate- to- severe lupus who have failed 
conventional immunosuppressant therapy due to the few 
treatment options available for this patient group (NHS 
ENGLAND A13/PS/a).14 However, the variable thera-
peutic success of rituximab highlights the need to refine 
therapies that target B cells to improve the outcome for 
patients with SLE.
The efficiency of B cell depletion following rituximab 
treatment has been shown to predict response in patients 
with lupus.4 15 16 Analysis of peripheral B cell subsets 
revealed that patients with lower plasmablast counts at 
6 months are more likely to have a sustained response 
without requiring retreatment.4 In the subset of SLE 
patients with high levels of anti- double stranded DNA 
(anti- dsDNA) antibodies, clinical relapse occurs at lower 
B cell numbers after treatment compared with before 
rituximab and is associated with higher proportions of 
repopulating plasmablasts in the peripheral blood.15 
Further investigation into the mechanism of rituximab 
has demonstrated that levels of the B cell cytokine BAFF 
(B cell activating factor) surge after B cell depletion.17 18 
Moreover, elevated serum BAFF levels can endure beyond 
initial B cell repopulation and distinguish lupus relapse 
from ongoing disease remission following rituximab.19 
In some lupus patients repeated cycles of rituximab 
resulted in ever higher levels of serum anti- dsDNA anti-
bodies, which were associated with increasing levels of 
serum BAFF.16 This observation raises the possibility that 
repeated rituximab treatments may result in more severe 
flares driven by BAFF.20 Thus, high BAFF levels post ritux-
imab could be limiting its effectiveness in some patients 
with SLE.
Clinical studies have demonstrated that BAFF is over-
expressed, either intermittently or persistently, in many 
patients with SLE irrespective of rituximab therapy21 22 
and serum levels correlate with serological and clinical 
indices of disease activity.23 In 2016, the BAFF- neutralising 
monoclonal antibody, belimumab was the first biolog-
ical licensed for the treatment of lupus following two 
large phase III clinical trials, BLISS 5224 and BLISS 
76.25 Treatment with belimumab after B cell depletion 
has been suggested as a potential therapeutic strategy 
for patients with SLE.20 We therefore designed a phase 
II clinical trial to assess the safety and effectiveness of 
this treatment regime for patients with lupus, the latter 
judged by a change in anti- dsDNA antibody levels as the 
primary outcome. Anti- dsDNA antibodies have been 
associated with disease activity in patients with SLE.14 26 27 
Secondary outcomes include incidence of adverse events, 
reduction in cumulative steroid intake and incidence of 
disease flares during the 52 week follow- up period. This 
trial will also assess the kinetics of B cell repopulation 
over the course of the trial.
MEthods And AnAlysIs
BEAT Lupus is a phase IIb, multicentre, UK based, 
randomised, double blind, placebo- controlled inter-
ventional clinical trial investigating the safety and effi-
cacy of belimumab (given for 12 months), 4 to 8 weeks 
after the first infusion of B cell depletion therapy (ritux-
imab). Rituximab is administered according to the NHS 
England interim clinical commissioning policy (NHS 
England A13/PS/a) and the British Society for Rheuma-
tology guideline for the management of systemic lupus 
erythematosus in adults,14 specifically two 1 g doses of 
rituximab given intravenously 2 weeks apart. The target 
population of the trial is patients with a diagnosis of lupus 
undergoing rituximab therapy as standard of care. The 
trial began recruitment in November 2016 and closed for 
recruitment in March 2019, all patients were recruited 
in England, with data collection of the primary outcome 
expected to end in March 2020. Collection of safety data 
will end in April 2020.
study population
Detailed inclusion and exclusion criteria are listed in 
box 1. In brief, patients are aged between 18 and 75 years 
with four or more criteria for SLE, according to the Amer-
ican College of Rheumatology (ACR) 1997 criteria or 
Systemic Lupus International Collaborating Clinics 2012 
criteria for lupus, or biopsy proven lupus nephritis with 
one additional supportive test on at least two occasions 
(positive antinuclear antibody, anti- dsDNA antibodies or 
anti- Smith antibodies).14 Patients had to have a history of 
anti- dsDNA antibodies detectable at least once in the past 
5 years. Participants had to be eligible for treatment with 
rituximab as per NHS England Commissioning Policy. A 
screening and assessment visit are performed before the 
first (of two) rituximab infusion, which is 4 to 8 weeks 
before randomisation (Day 0, figure 1). A second screen 
is performed no more than 10 days before randomis-
ation to confirm eligibility (eg, excluding patients who 
required intravenous antibiotics for infections devel-
oping after rituximab or low IgG levels, see box 1). Prior 
use of rituximab is allowed, but not within 6 months of 
initial screening.
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box 1 Continued
12. History of cervical dysplasia cervical intraepithelial neoplasia- CIN 
grade III, cervical high- risk human papillomavirus (HPV) or abnor-
mal cervical cytology other than abnormal squamous cells of un-
determined significance within the past 3 years. The participant 
will be eligible after the condition has resolved (eg, follow- up HPV 
test is negative or cervical abnormality has been effectively treated 
>1 year ago).
13. Severe, progressive or uncontrolled renal, hepatic, haematological, 
gastrointestinal, pulmonary, cardiac or neurological disease or, in 
the investigator’s opinion, any other concomitant medical condition 
or significant abnormal laboratory value that places the participant 
at risk by participating in this trial with the exception of diseases or 
conditions related to active SLE.
14. Comorbidities not lupus related currently requiring systemic corti-
costeroid therapy.
15. Evidence of serious suicide risk including any history of suicidal 
behaviour in the last 6 months and/or any suicidal ideation in the 
last 2 months or who in the investigator’s judgement, pose a sig-
nificant risk.
16. History of an anaphylactic reaction to parenteral administration of 
contrast agents, human or murine proteins or monoclonal antibod-
ies. Current drug or alcohol abuse or dependence, or a history of 
drug or alcohol abuse or dependence within 364 days prior to Day 
0.
17. White blood cells <1.5 x 109/L, neutrophils <1 x 109/L measured 
up to 10 days before Day 0.
18. A history of major organ transplant or haematopoietic stem/cell/
marrow transplant or renal transplant.
box 1 Participant inclusion and exclusion criteria 
(randomisation to belimumab or placebo occurs at day 0)
Inclusion criteria
1. Age between 18 and 75 years.
2. Participants with four or more criteria for systemic lupus erythe-
matosus (SLE) according to the American College of Rheumatology 
1997 criteria or Systemic Lupus International Collaborating Clinics 
2012 criteria or biopsy proven lupus nephritis with one additional 
supportive test on at least two occasions (positive antinuclear anti-
body, anti- dsDNA antibodies or anti- Smith antibodies).
3. History of anti- dsDNA antibodies detectable at least once in the past 
5 years prior to screening (ELISA test is preferable for anti- dsDNA 
antibody testing).
4. Participants are due to be treated with the first infusion of B cell de-
pletion therapy (rituximab) 4 to 8 weeks before randomisation (Day 
0). Previous use of rituximab is allowed prior to this cycle but not 
within 6 months of screening.
5. No contraindications to the use of belimumab.
6. Ability to provide informed consent.
Exclusion criteria
1. Severe ‘critical’ SLE flare defined as British Isles Lupus Assessment 
Group A flare in central nervous system or any SLE manifestation 
requiring more immunosuppression than allowed within the proto-
col in the physician's opinion.
2. Pregnancy and/or breastfeeding patients.
3. At risk of pregnancy and unwilling to use an acceptable form of 
birth control contraception.
4. Prior use of belimumab, atacicept or any biological therapy (except 
rituximab, but no other B cell depleting therapies).
5. Participation in any other interventional trial within the last 6 
months.
6. Estimated glomerular filtration rate <30 mls/min at screening.
7. Active infections, including but not limited to:
 – Current or past infection with hepatitis B or C as defined by:
Hepatitis B surface antigen positive.
Hepatitis B surface antibody positive and hepati-
tis B core antibody positive.
Hepatitis C antibody positive.
 – Historically positive HIV test or test positive at screening for HIV.
 – Active tuberculosis.
8. Infection history:
 – Currently on any suppressive therapy for a chronic infection 
(such as tuberculosis, pneumocystis, cytomegalovirus, herpes 
simplex virus, herpes zoster and atypical mycobacteria)
 – Hospitalisation for treatment of infection within 60 days of Day 0.
 – Use of parenteral (intravenous or intramuscular) antibiotics (anti- 
bacterials, antivirals, anti- fungals or anti- parasitic agents) within 
30 days of Day 0.
 – Receipt of a live- attenuated vaccine within 3 months of Day 0.
 – In the investigator’s opinion, participants that are at high risk for 
infection (including but not limited to in dwelling catheter, dys-
phagia with aspiration, decubitus ulcer, history of prior aspiration 
pneumonia or recurrent severe urinary tract infection).
9. IgG levels below 4.0 g/L, IgA level < 10 mg/dL (IgG and IgA test 
must be performed no more than 10 days before Day 0).
10. Primary immunodeficiency.
11. History of malignant neoplasm within the last 5 years.
Continued
randomisation and blinding
BEAT Lupus is a double- blind trial. Only the local phar-
macist, the unblinded site monitor and the trial statisti-
cian will be unblinded to the treatment allocation. All 
other members of the trial team and patients are blinded 
to the trial medication throughout the trial. Unblinding 
will only occur if a participant experiences a serious 
adverse event (SAE) for which the clinical management 
of the SAE will be facilitated by the unblinding of the 
participant’s treatment allocation. All recruited partici-
pants will be given a card with contact details for the trial 
team including emergency contact 24 hours a day, 7 days 
per week. In the event of unblinding becoming neces-
sary, emergency unblinding can occur at any time via the 
24 hours web- based service provided by Sealed Envelope 
(https://www. sealedenvelope. com/).
After providing written informed consent, participants 
are randomised to belimumab or placebo treatment 
using a secure online randomisation service provider, 
Sealed Envelope. The trial statistician will generate a list 
of unique BEAT Lupus infusion codes which will be sent 
to Sealed Envelope. The trial pharmacist will dispense 
the randomised infusion for each participant in accor-
dance with their infusion code. Randomisation will be 
performed using minimisation, incorporating a random 
element to ensure balance in the stratifying variables 
between the two randomised groups, while retaining an 
element of unpredictability. Stratifying variables are: CD19 
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Figure 1 Schedule of trial visits.
count after rituximab at randomisation (<0.01×109/l vs 
>0.01×109/l) to account for variability in B cell depletion 
which would affect response, anti- dsDNA (positive or 
negative at screen) and whether patients have active renal 
disease at screening.
trial treatment
Participants either receive intravenous belimumab or 
placebo 4 to 8 weeks after the first of two infusions of B 
cell depletion therapy (one cycle rituximab) administered 
by trial nurses. The total treatment period (belimumab or 
placebo) will be 52 weeks (last infusion of belimumab or 
placebo at week 52) followed by a safety visit at week 56. 
In the active therapy arm, participants will receive beli-
mumab according to the standard dosage regime. The 
recommended dosage regimen is 10 mg/kg at 2 week 
intervals for the first three doses and at 4 week intervals 
thereafter. The participants in the placebo group receive 
the same volume of normal saline infusions (indistinguish-
able from active treatment) at the same time points as the 
active treatment group. The visit schedule is summarised 
in figure 1. Trial treatment may be stopped in the event of 
unacceptable toxicity or adverse event.
Concomitant medications
Before randomisation, which includes the period when 
rituximab is administered, treatment is entirely at the 
physician’s discretion, though the rituximab dose is fixed 
by NHS England (1 g administered on two occasions, 
2 weeks apart). All medication is recorded. From the day 
of randomisation (Day 0, see figure 1), the maximum 
dose of mycophenolate is 1 g/day with a suggested dose 
reduction to 500 mg/day at 3 months or as soon as 
possible thereafter. The maximum dose of azathioprine 
after randomisation is 1 mg/kg with a suggested dose 
reduction to 0.5 mg/kg by 3 months or as soon as possible 
thereafter. The maximum dose of methotrexate allowed 
is 15 mg/week with a dose reduction to 10 mg/week by 
3 months or as soon as possible thereafter. Only one of 
these three immunosuppressant drugs (azathioprine, 
methotrexate and mycophenolate) can be administered 
post randomisation. No other immunosuppressants (eg, 
cyclophosphamide, tacrolimus) are allowed after rando-
misation except in the case of severe flare. Background 
anti- malarial drugs are permitted but no new anti- 
malarials can be started after randomisation. Mepacrine 
(quinacrine) is acceptable for skin problems resistant to 
hydroxychloroquine and both can be combined if this 
regime was started before randomisation. No change in 
dose of the anti- malarials can be made after randomisa-
tion. Participants will be permitted to receive up to 20 mg 
prednisolone/day from randomisation. It is strongly 
encouraged that prednisolone should be reduced by 
50% by 6 months post randomisation, with a maximum 
dose of 5 mg/day recommended at 6 months if possible. 
Participants who flare with one British Isles Lupus Assess-
ment Group (BILAG) A or two BILAG B scores will be 
permitted to receive other therapies or increased pred-
nisolone at the discretion of the treating physician. 
Further cycles of rituximab are not allowed during the 
trial even in the event of a severe disease flare. Centres 
are encouraged to follow the British Society for Rheuma-
tology guidelines for the management of systemic lupus 
erythematosus in adults.14
trial endpoints
The primary outcome measure is anti- dsDNA antibody 
levels at 52 weeks. Anti- dsDNA antibodies often correlate 
with disease activity.14 26 27 This biomarker was also chosen 
due its correlation with BAFF levels in participants post 
B cell depletion therapy.19 Serum anti- dsDNA antibodies 
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box 2 outcome measures
Primary outcome measures
Anti- doublestranded DNA (anti- dsDNA) antibody levels at 52 weeks.
secondary outcome measures
1. Anti- dsDNA antibody levels at 24 weeks.
2. Proportion of participants with any adverse events by 52 weeks.
3. Proportion of participants with any serious adverse events by 52 
weeks.
4. Proportion of participants with any infections by 52 weeks.
5. Proportion of participants with a severe disease flare (defined as ≥ 
one British Isles Lupus Assessment Group (BILAG) A) by 52 weeks.
6. Proportion of participants with a severe (defined as ≥ one new 
BILAG A) or a moderate disease flare (defined as ≥ two new BILAG 
Bs) by 52 weeks.
7. Time to severe disease flare.
8. Proportion of participants with a severe disease flare by 24 weeks.
9. Systemic Lupus Erythematosus Disease Activity Index 2000 at 52 
weeks.
10. Subject Global Assessment of Disease Activity at 52 weeks.
11. C3 levels at 52 weeks.
12. Immunoglobulin levels at 52 weeks.
13. Cumulative steroid dose from randomisation to 52 weeks.
14. Proportion of participants decreasing steroid dose at randomisation 
by 50% without experiencing a flare, or if below 10 mg/day at ran-
domisation reducing dose to 5 mg/day or less at 52 weeks.
15. Lupus Quality of Life, SF-36 at 52 weeks
16. Columbia Suicide Severity Rating Scale to assess suicidality risk 
at 52 weeks.
Exploratory outcomes
1. B cell activating factor (measurement of RNA from whole blood) at 
52 weeks.
2. Kinetics of B cell repopulation.
are analysed using the DIASTAT anti- dsDNA ELISA. All 
samples are tested in the same central lab at University 
College London (UCL).
Secondary outcome measurements include anti- dsDNA 
antibody levels at 24 weeks and the proportion of partici-
pants with serious adverse events (box 2). The proportion 
of participants with a moderate (defined as ≥2 new BILAG 
Bs) or severe disease flare (defined as ≥1 new BILAG 
A) by 24 and 52 weeks following randomisation will be 
assessed, as will the time to a disease flare. Patients who 
have a severe disease flare will be invited to an additional 
visit where standard trial data, including serum for the 
primary endpoint analysis, is collected, particularly if they 
are withdrawing from trial therapy and may be treated 
with therapies that are not allowed according to the 
protocol for example, rituximab and cyclophosphamide.
Disease activity will be assessed using the British Isles 
Lupus Assessment Group (BILAG-2004) disease activity 
index28 and Systemic Lupus Erythematosus Disease 
Activity Index 2000.29 C3 and immunoglobulin levels will 
be recorded. As part of the assessment of response to 
treatment, we shall calculate the cumulative steroid dose 
during treatment from randomisation and the propor-
tion of participants decreasing their steroid dose by 50% 
without flaring from randomisation; or if below 10 mg/
day at randomisation reducing steroid dose to 5 mg/day 
or who discontinue glucocorticoids with stable disease. 
Lupus Quality of Life and SF-36 will be used as patient 
reported outcome measures. ColumbiaSuicide Severity 
Rating Scale will be used to assess suicidality risk.
data collection and management
All participant data will be collected by members of the 
clinical trial team as described in the Delegation Log. 
Data will be recorded on a paper Case Report Forms 
and entered in to the secure Clinical Trial Database via 
a secure web interface. All data will be handled in accor-
dance with the Data Protection Act 1998. The partici-
pant’s initials, date of birth and participant identification 
number, will be used for identification.
Data entry, coding and security will be the responsibility 
of a dedicated data manager based. A custom designed 
database will be created (using InferMed’s MACRO V4) 
to store all trial data. This will be compliant with all neces-
sary regulatory requirements including an audit trail to 
record all date/time stamped corrections accompanied 
by justification/explanation for any data amendments. 
Monitoring visits will be conducted by the central trial 
team at all recruiting sites at regular intervals, in accor-
dance with regulatory requirements. The trial may be 
audited independently by the Medicines & Healthcare 
Products Regulatory Agency.
trial sample size calculation
We aim to recruit up to 56 SLE participants (the original 
sample size of 50 was increased to account for a higher 
than expected dropout rate) and randomise 28 partici-
pants to receive belimumab after rituximab and 28 partic-
ipants to receive placebo after rituximab. The primary 
outcome is the estimated difference in anti- dsDNA 
binding antibody levels at 12 months, adjusted for anti- 
dsDNA binding levels at screening. Sample size calcula-
tions were performed using Stata Release 13 assuming 
that anti- dsDNA binding antibody levels are log normally 
distributed. The SD of anti- dsDNA and the correlation 
structure assumed were based on two sets of data (a) the 
study of 35 participants by Carter et al19 and (b) unpub-
lished data provided by Prof D Isenberg for 67 partici-
pants before and 6 months after B cell depletion therapy 
(table 1).
On the natural log scale the SD of anti- dsDNA at the end 
of treatment was taken to be 1.7 based on the above data. 
The correlation between before rituximab and final log 
anti- dsDNA was taken to be 0.55 also based on the above. 
Twenty- two evaluable participants per group would be 
able to detect a difference of 1.2 in anti- dsDNA binding 
antibody levels on the natural log scale at the 5% signifi-
cance level with 80% power. Assuming that 20% of partic-
ipants fail to attend the 52 week follow- up visit, and taking 
account of the correlation between screening measure-
ments and 52 week measurements, we aim to recruit 28 
participants per group. For example, if we assume that 
Protected by copyright.
 o
n
 January 16, 2020 at Barnes Library M
edical School.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032569 on 16 December 2019. Downloaded from 
6 Jones A, et al. BMJ Open 2019;9:e032569. doi:10.1136/bmjopen-2019-032569
Open access 
Table 1 SD and correlations for loge anti dsDNA
Data set Time point
Log 
mean Log SD Correlation
Isenberg 
(n=67)
Before 
rituximab
6.036 1.393
Follow- up 5.189 1.500 0.612
Carter 
(n=35)
Before 
rituximab
5.091 1.676
Follow- up 5.225 1.781 0.527
there will be no change in anti- dsDNA levels in the belim-
umab group, then we would be able to detect an increase 
of 232% in the placebo group as significantly different. 
To place this increase in context, Carter et al showed that 
the difference in anti- dsDNA binding antibody levels on 
the natural log scale between those participants who did 
and did not have a flare was 1.928, corresponding to a 
588% increase in anti- dsDNA binding levels in partici-
pants with a disease flare.19
statistical analysis
A Consolidated Standards of Reporting Trials diagram will 
be used to describe the course of participants through the 
trial (figure 1). Characteristics at screening and randomi-
sation will be summarised by treatment group.
The analysis of the primary outcome will be done 
using linear regression to estimate the difference in log 
anti- dsDNA levels between the two groups at 52 weeks, 
adjusting for the stratifying variables anti- dsDNA (at 
screening, pre- rituximab), BILAG category (renal, 
non- renal) (at screening, pre- rituximab) and CD19 
count (at randomisation). The analysis will be done on 
the intention- to- treat principle; all available 52 week 
measurements will be included regardless of patient’s 
adherence to their randomised treatment. If withdrawals 
from follow- up before week 52 exceed 10%, a supportive 
analysis of the primary outcome will be done using 
multiple imputation (with 52 week anti- dsDNA imputed 
using baseline and any 12 and 24 weeks measurements 
where available and other auxiliary information) to eval-
uate the sensitivity of the results to any differential loss 
to follow- up. Another supportive sensitivity analysis will 
be done to estimate the treatment effect for only those 
patients who adhered to their allocated treatment for 
52 weeks. Additionally, if material differences are found 
between treatment groups in cumulative prednisolone 
dose from randomisation (p<0.1), mediation analyses will 
be done to evaluate whether the observed effect of beli-
mumab on anti- dsDNA levels is mediated by changes in 
prednisolone dose.
A similar modelling approach will be adopted for 
the analysis of other continuous outcomes measured 
at screening (before rituximab) and at 52 weeks. Fish-
er’s exact test will be used to compare proportions. 
Two sample t- tests or Mann- Whitney U tests, depending 
on the distribution of the data, will be used to evaluate 
continuous outcomes compared only at the end of the 
trial. Kaplan- Meier survival curves will be produced for 
comparisons of time to an event. The statistical analysis 
will be performed using Stata.
Ethical considerations
The trial will be conducted in accordance with ethical 
principles derived from Good Clinical Practice Guide-
lines, including the Declaration of Helsinki. Written 
informed consent (see online supplementary file for 
consent form) will be collected from all patients by an 
approved study nurse or physician before the start of any 
study procedures. Patients will be assigned a participant 
identification number and all patient information trans-
ferred to the sponsor will contain this number, patient 
initials and date of birth. All SAEs will be reported to the 
sponsor within 24 hours. All agreed substantial protocol 
amendments, will be documented and submitted for 
ethical and regulatory approval prior to implementa-
tion and communication to sites. Protocol V.5 dated 21st 
January 2019 is the current protocol version and has been 
approved.
dissemination
Trial information is available at https://www. isrctn. com/ 
ISRCTN47873003 including study sites all of which are in 
England, and the results of this trial will be submitted for 
publication in relevant peer- reviewed publications. Key 
findings will also be presented at national and interna-
tional conferences. Published results will be disseminated 
to investigators at participating sites, who will further 
disseminate the results to trial participants on request. 
Authorship of publications will adhere to International 
Committee of Medical Journal Editors guidelines.
Patient and public involvement
Feedback gathered from focused patient involvement 
meetings was used to inform the design of this trial. 
Patients recognised the need for improving therapies for 
SLE. Our patient partners suggested that the inclusion 
and exclusion criteria should not represent a significant 
barrier to recruitment and that the trial should be as close 
to ‘real- world’ practise as possible. Two patient advisors 
are members of the Trial Steering Committee.
trial steering committee
The Trial Steering Committee (TSC) is led by inde-
pendent chair (Professor Raashid Luqmani) from a 
non- participating centre, and includes an independent 
statistician (Professor John Bankart) and one indepen-
dent clinical expert in SLE (Dr Ceril Rhys- Dillon) as well 
as the Chief Investigator (Professor Michael Ehrenstein) 
and members of the trial team, some principal investiga-
tors from the participating sites and two patient partners. 
The TSC provides expert oversight of the trial, agreement 
of final protocol, reviewing progress of study, recruitment 
and retention rates and agreeing changes to the protocol 
to facilitate the smooth running of the study. The TSC 
together with the Chief Investigator will oversee the 
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timely analysis and publication of the main trial results 
and will review requests for data sharing. Full composi-
tion of the TSC and terms of reference are available from 
the corresponding author.
data monitoring committee
An Independent Data Monitoring Committee (IDMC) is 
chaired by Professor Richard Watts (independent clinical 
expert) and includes Professor Vern Farewell (indepen-
dent statistician) and Professor Robert Moots (indepen-
dent clinical expert) together with the trial statistician. 
During the period of recruitment to the study, interim 
analyses of accruing data will be supplied, in strict confi-
dence, to the IDMC. The IDMC will advise the TSC of 
any issues to safeguard the interests of trial participants 
including assessment of SAEs and flare rates after 50% 
of the participants have been recruited and followed up 
for 6 months to determine whether recruitment should 
continue (interim safety analysis). All SAEs will be 
reported in real time to the IDMC with a clinical narra-
tive, including an assessment of attribution to belimumab. 
Full composition of the IDMC and terms of reference are 
available from UCL Comprehensive Clinical Trials Unit.
dIsCussIon
This clinical trial was developed through investigation and 
analysis of clinical and laboratory data of lupus patients 
receiving rituximab. In particular, we noted increased 
serum BAFF levels correlated with a rise in anti- DNA anti-
bodies at the time of flare in lupus patients post ritux-
imab.19 We therefore hypothesised that lupus patients 
treated with belimumab following rituximab therapy 
will have lower anti- dsDNA antibody levels compared 
with those that have received rituximab alone, and that 
this combination would have greater efficacy than ritux-
imab alone. Given the paucity of novel therapies, and the 
many clinical trials that have failed to show efficacy for 
SLE, a combination of biological therapies with comple-
mentary effects given in succession may be required to 
control disease. If the results of this trial are promising, 
a larger trial will be required of sufficient power to 
detect improved clinical outcomes. Indeed, a larger trial 
is already underway (BLISS BELIEVE NCT03312907) 
testing whether rituximab given after belimumab confers 
an additional benefit compared with belimumab alone.30 
The order of administration of these two biologics in 
BLISS BELIEVE is reversed compared to BEAT LUPUS, 
and there is no rituximab alone arm. The administra-
tion of rituximab first allows for the detection of adverse 
events that occur in the 4 to 8 week period after ritux-
imab and before randomisation. A second screen 7 to 10 
days before randomisation will exclude patients based 
on these adverse events. CALIBRATE (NCT02260934), 
a clinical trial in lupus nephritis uses a similar sequence 
of these two biologics to the trial reported here, though 
cyclophosphamide is administered with the rituximab, 
and higher doses of concomitant immunosuppressive 
medications are allowed.
Recruitment to lupus trials has been challenging in the 
UK, and few academic led interventional SLE trials in the 
UK have met their recruitment target. The last academic 
led lupus trial in the UK not subject to early termination 
because of poor recruitment commenced in 1997 and 
completed recruitment in 2005 (though even this open 
label trial’s recruitment target had to be reduced due to 
slow enrolment).31 We endeavoured to optimise recruit-
ment by designing a protocol that would be as close 
to real life clinical practice as possible. Consequently, 
there are no therapeutic restrictions before patients are 
randomised (to receive either belimumab or placebo) 
giving freedom to the treating physician including the 
possibility of administering high dose corticosteroids in 
conjunction with rituximab. Rituximab had to be admin-
istered 4 to 8 weeks before randomisation and is admin-
istered in accordance with the NHS England’s Interim 
Commissioning Policy (NHS ENGLAND A13/PS/a) for 
patients with refractory lupus.14 This policy only allows 
rituximab to be given to patients who have failed to 
respond adequately to either mycophenolate or cyclo-
phosphamide, unless contraindicated, or requiring unac-
ceptably high doses of corticosteroids. Thus, the results of 
this trial will be relevant to lupus patients that are refrac-
tory or intolerant to conventional treatment, the patient 
group for which this combination therapy is most likely to 
be funded. The study provides information about rates of 
recruitment to lupus trials in England which could inform 
the development and feasibility of other UK based trials 
planned in the future. Recruitment was aided through 
NHS England’s policy applicable to biological therapies 
for SLE which encourages physicians and their patients 
to consider interventional clinical trials (NHS ENGLAND 
A13/PS/a).14
The trial protocol offers physicians some flexibility with 
the use of concomitant immunosuppressant and oral 
prednisolone after randomisation. However, because of 
safety concerns, and to maximise the chances of revealing 
any potential difference between the two treatment arms, 
corticosteroids are limited to a maximum dose of 20 mg/
day at randomisation and it is strongly encouraged to 
taper the dose by at least 50% by 6 months. Moreover, 
immunosuppressant doses are also restricted. It can be 
difficult to achieve reductions in both corticosteroids and 
immunosuppressants in patients who, by the nature of 
the inclusion criteria, are more resistant to therapy. Our 
strategy is to advise that reduction in corticosteroid dose 
should be prioritised over tapering immunosuppressants 
due to the former’s more problematic side effects, and its 
ability to mask the difference between treatment arms in 
lupus trials.
This trial has some limitations. First, the sample size is 
relatively small because at the time of the trial’s incep-
tion there were no published safety data on the combina-
tion of rituximab and belimumab and an earlier phase, 
smaller trial was advised. Therefore, the trial is powered 
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on anti- DNA antibodies rather than a clinical endpoint. 
To limit the risk of adverse events due to immunosuppres-
sion, the dose of concomitant immunosuppressive medi-
cation is lower than routinely prescribed for patients with 
active disease, particularly renal patients receiving myco-
phenolate. This may reduce recruitment of patients with 
active nephritis by some physicians, although this restric-
tion in dosage could also be an advantage with respect 
to distinguishing between active drug and placebo. 
The serological inclusion criteria enable patients with a 
confirmed positive dsDNA antibody within the last 5 years 
to participate in the trial rather than patients who have 
raised anti- DNA antibodies at screen. This approach was 
taken to maximise recruitment but also with the recog-
nition that flares post rituximab can, in a proportion 
of patients, be associated with increased anti- DNA anti-
body levels above that observed when rituximab is first 
commenced.15
The development of this trial has arisen directly from 
analysis of the immunological changes following B cell 
depletion therapy. Building on this experimental medi-
cine approach, analysis of B cell phenotype has been 
incorporated into this trial to understand how sequen-
tial targeting of B cells and BAFF affect B cell numbers 
and phenotype. If the overall results from this trial are 
encouraging, a larger definitive trial using time to flare 
as the primary outcome may be considered after taking 
into account the results from other similar trials currently 
underway. The increasing interest in this combination 
therapy has the potential to offer a novel treatment 
option for patients with active lupus.
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